CCP
QDEL icon

Corient Capital Partners’s QuidelOrtho QDEL Stock Holding History

Corient Capital Partners’s Portfolio QDEL Stock Details QDEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,000
Closed -$675K – 743
2022
Q1 		$675K Buy
+6,000
New +$639K 0.04% 325

Other funds holding QDEL

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Corient Capital Partners's QDEL Position: Q2 2022 in Review

Corient Capital Partners sold out of QuidelOrtho (QDEL) in Q2 2022, closing a stake of 6,000 shares — an estimated $675K sold.

Corient Capital Partners first reported a position in QDEL in Q1 2022 and held it in 1 quarter. The position peaked at $675K in Q1 2022. 347 funds tracked by Wall St. Rank hold QDEL as of Q2 2022.

  • Corient Capital Partners reported no remaining QuidelOrtho position as of Q2 2022 after selling out during the quarter.
  • Corient Capital Partners sold 6,000 QuidelOrtho shares in Q2 2022, an estimated $675K.
  • Corient Capital Partners first reported a position in QuidelOrtho in Q1 2022 and held it in 1 quarter.
  • Corient Capital Partners's QuidelOrtho position peaked at $675K in Q1 2022.
  • 347 funds tracked by Wall St. Rank held QuidelOrtho as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.